BioNTech (NASDAQ:BNTX) Stock Price Down 1.3% – Time to Sell?

BioNTech SE (NASDAQ:BNTX) was down 1.3% during mid-day trading on Wednesday . The company traded as low as $115.51 and last traded at $115.91. Approximately 88,213 shares were traded during trading, a decline of 89% from the average daily volume of 805,779 shares. The stock had previously closed at $117.39.

Analyst Ratings Changes

BNTX has been the subject of several analyst reports. BMO Capital Markets reaffirmed an “outperform” rating on shares of BioNTech in a research note on Monday, December 2nd. Canaccord Genuity Group upped their price target on BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a research note on Wednesday, November 27th. JPMorgan Chase & Co. dropped their price objective on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 26th. UBS Group raised their target price on shares of BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 18th. Finally, Morgan Stanley upgraded shares of BioNTech from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $93.00 to $145.00 in a research note on Tuesday, September 24th. Four investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, BioNTech has a consensus rating of “Moderate Buy” and an average target price of $140.76.

BioNTech Trading Down 2.5 %

The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $27.20 billion, a PE ratio of -54.49 and a beta of 0.22. The business’s fifty day moving average price is $113.66 and its 200 day moving average price is $100.66.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $514.08 million. During the same period in the prior year, the firm posted $0.73 earnings per share. The business’s quarterly revenue was up 38.9% compared to the same quarter last year. As a group, analysts expect that BioNTech SE will post -3.72 EPS for the current fiscal year.

Institutional Trading of BioNTech

Institutional investors and hedge funds have recently made changes to their positions in the company. Planning Capital Management Corp grew its position in BioNTech by 45,000.0% during the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after acquiring an additional 450 shares during the period. Blue Trust Inc. increased its position in BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after purchasing an additional 388 shares in the last quarter. GAMMA Investing LLC raised its holdings in BioNTech by 21.7% in the third quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock valued at $74,000 after buying an additional 111 shares during the period. Clear Harbor Asset Management LLC acquired a new position in BioNTech during the third quarter valued at approximately $210,000. Finally, Probity Advisors Inc. purchased a new stake in BioNTech during the third quarter worth approximately $216,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.